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Summary
INTRODUCTION: Acute painful diabetic neuropathy
(APDN) is a distinctive diabetic polyneuropathy and con-
sists of two subtypes: treatment-induced neuropathy (TIN)
and diabetic neuropathic cachexia (DNC). The character-
istics of APDN are (1.) the small-fibre involvement, (2.)
occurrence paradoxically after short-term achievement of
good glycaemia control, (3.) intense pain sensation and (4.)
eventual recovery. In the face of current recommendations
to achieve quickly glycaemic targets, it appears necessary
to recognise and understand this neuropathy.
METHODS AND RESULTS: Over 2009 to 2012, we re-
ported four cases of APDN. Four patients (three males and
one female) were identified and had a mean age at onset
of TIN of 47.7 years (±6.99 years). Mean baseline HbA1c
was 14.2% (±1.42) and 7.0% (±3.60) after treatment. Mean
estimated time to correct HbA1c was 4.5 months (±3.82
months). Three patients presented with a mean time to
symptom resolution of 12.7 months (±1.15 months). One
patient had an initial normal electroneuromyogram
(ENMG) despite the presence of neuropathic symptoms,
and a second abnormal ENMG showing axonal and myelin
neuropathy. One patient had a peroneal nerve biopsy show-
ing loss of large myelinated fibres as well as unmyelinated
fibres, and signs of microangiopathy.
CONCLUSIONS: According to the current recommenda-
tions of promptly achieving glycaemic targets, it appears
necessary to recognise and understand this neuropathy.
Abbreviations
ASFSN small fibre sensory neuropathy
APDN acute painful diabetic neuropathy
DSP distal symmetric polyneuropathy
DNC diabetic neuropathic cachexia
ENMG electroneuromyography
GAD glutamic acid decarboxylase
HbA1c glycated haemoglobin
IENFd intraepidermal nerve fibre density
SNRI serotonin-noradrenaline reuptake inhibitor
TIN treatment-induced neuropathy
Based on our observations and data from the literature we
propose an algorithmic approach for differential diagnosis
and therapeutic management of APDN patients.
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Introduction
Peripheral neuropathies are well-known complications of
diabetes [1]. The two most common types are the chronic,
slowly progressive, length-dependent, axonal (or dying
back) polyneuropathy involving all nerve fibre types, often
referred to as distal symmetric polyneuropathy (DSP), and
the more recently recognised small fibre neuropathy [2].
Less common types include subacute onset diabetic lum-
bosacral radiculoplexus neuropathy [3], truncal neuropathy
resembling herpes zoster, and acute painful diabetic neuro-
pathy (APDN). APDN is reported in diabetes type 1 and 2
patients and is associated with the rapid decrease of high
glycaemic levels. APDN was initially reported in 1933 by
Caravati [4] as “insulin neuritis” in a woman with diabetes
who had acute pain in the lower extremities that appeared
4 weeks after insulin initiation. The pain resolved with-
in 3 days of stopping insulin concurrent with severe hy-
perglycaemia. Since then, similar observations have been
reported either in patients treated with exogenous insulin
[5–8] or oral antidiabetic agents or even after a change
of diet [9, 10], suggesting that insulin itself might not be
the primary inducing factor. Therefore “treatment-induced
neuropathy” (TIN) appears to be a more appropriate term
for this subtype of APDN. A recent investigation of TIN
in 16 patients suggested a predominantly nociceptive and
autonomic small nerve neuropathy [11].
Four decades after the first TIN description, Ellenberg re-
ported a case series of 6 patients with painful diabetic
neuropathy, depression and cachexia arising at the time of
clinical diagnosis of diabetes [12]. Since then several cases
with a similar history and clinical picture have been re-
ported, which is described as diabetic neuropathic cachexia
(DNC) and considered a subtype of APDN [13–15].
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We report four cases of APDN and include pathological
and electrophysiological descriptions at the time of dia-
gnosis and at follow-up in one case; thus we can better de-
lineate the type of neuropathy and its evolution over time.
Our aim is to provide an algorithmic approach and dia-
gnostic criteria for evaluation and differential diagnosis of
a patient with APDN.
Methods
Cases of APDN were identified in Lausanne and Geneva
University Hospitals Neuromuscular Units over a 5-year
period from 2009 to 2013. Charts of these patients were
analysed for history, and clinical, laboratory, electro-
physiological and pathological findings. The following
were recorded: age at onset of APDN, diabetes type, dia-
betes duration; HbA1c prior to and after treatment initi-
ation, estimated time to correct HbA1c, onset of neuro-
pathic pain, diabetic and pain medications, other symptoms
such as cachexia and/or dysautonomic symptoms; electro-
physiological findings (electroneuromyography [ENMG]
descriptions), intraepidermal nerve fibre density (IENFd)
and sural nerve biopsy findings if reported.
Results
Based on the average annual activity of our two neuromus-
cular units and on the proportion of diabetic patients ob-
served in a sample of patients seen over a 1-week period,
we estimated the number of diabetic patients examined in
our neuromuscular units from 2009 to 2013 to be approx-
imately 1,500. This corresponds to a rough prevalence of
around 10% for diabetes in our neuromuscular units, which
Figure 1
Distal lower limb skin and sural nerve biopsy in normal subject
compared with patient 4.
A: Distal lower limb biopsy of a normal subject (FO). Magnification
40x. Average intraepidermal nerve fibre density (IENFDd) = 12.7
s/mm.
B: Distal lower limb skin biopsy of patient 4. Note rarefaction of
intraepidernal nerve fibres. Magnification 40x. Average IENFd = 2.8
s/mm.
C: Sural nerve biopsy of patient 4. Optical microspcopy
(haematoxylin and eosin staining, orginal magnification 40x). Note
microthrombosis of vasa vasorum (white arrow).
D: Sural nerve biopsy of patient 4, electron microscopy. Severe loss
of myelinated and unmyelinated axons.
is nearly double the admitted extrapolated prevalence of
diabetes in our country in 2011 of 4.9% [16]. Four patients
(three male and one female) fulfilling criteria for APDN
could be detected over this 5-year period. Table 1 shows
the patient characteristics. Mean age at onset of APDN
symptoms was 47.7 years (±6.99), 50% (n = 2) of pa-
tients had type 1 diabetes and 50% (n = 2) type 2 diabetes.
Mean baseline HbA1c was 14.2% (±1.42; reference value
4.8%–5.9%) before treatment initiation and 7.0% (±3.60%)
after treatment. Mean estimated time to correct HbA1c was
4.5 months (±3.82 months). Time for resolution of symp-
toms in three patients was 12.7 months (±1.15 months).
Neuropathic pain management included specific pharma-
cological treatment (anticonvulsants, antidepressants and
opioids).
Detailed case reports
Case 1
A 44-year-old African male was diagnosed with type 1 dia-
betes after 2 weeks of polydipsia, polyuria and generalised
weakness. The initial blood glucose value was 24 mmol/
l. Subcutaneous insulin therapy was started and symptoms
resolved rapidly. Glycated haemoglobin (HbA1c) de-
creased from 15.1% to 7.2% within 5 months. After 4 to
6 weeks of insulin treatment, he complained of intermit-
tent sharp shooting pain and a severe burning sensation in
the soles of both feet, associated with intense discomfort to
touch sensation in both legs, which propagated upwards to
the thighs. Weight loss of 11 kg in 6 months associated with
depression was reported. Investigations to identify a tu-
mour, or infectious, digestive or endocrinological aetiology
were all negative except for vitamin D deficiency. Neurolo-
gical examination revealed absent Achilles tendon reflexes
on both sides with no motor or sensory deficits. Orthostat-
ic hypotension was noted. ENMG examination with stand-
ard nerve conduction studies was normal. Pregabalin (300
mg/d) and gabapentin (3 x 300 mg/d) were not effective
for the lower limb pain. With duloxetine (60 mg/d) and
opioids the neuropathic pain gradually improved but nev-
er resolved completely. Weight regain was 2 kg. After 5
months of therapy ENMG was performed a second time be-
cause of persistent symptoms, which disclosed marked ab-
normalities suggestive of an axonal and myelinic sensory
motor polyneuropathy. Amplitudes of motor and sensory
responses recorded on distal parts of the lower limbs and
nerve conduction velocities were markedly decreased.
There was diffuse hypoexcitability of nerve trunks. With
the same medication, mild improvement of the pain was
gradually observed, over a 1-year follow-up.
Case 2
A 57-year-old Caucasian male with a 5-year history of
poorly controlled type 2 diabetes and alcohol abuse com-
plained of tingling and burning in the feet and erectile dys-
function. Clinical examination showed decreased pallaes-
thesia of 4/8. HbA1c was 12.0%. He adopted a healthier
lifestyle by avoiding alcohol and became compliant with
medications. Subsequently, his HbA1c fell from 12% to
8% between April and November 2009 and he described
several episodes of postprandial symptomatic hy-
poglycaemia three to four times a week. In the meantime,
the polyneuropathy symptoms worsened with increased
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pain, symmetric paraesthesia and hyperaesthesia of the
lower limbs, and nocturnal leg cramps. He also reported
symptoms of gastroparesis including early satiety and post-
prandial fullness. Symptoms decreased with dietary
change. The neuropathy manifestations gradually im-
proved, disappearing almost completely after 14 months
without therapy.
Case 3
A previously healthy 49-year-old male was diagnosed with
type 2 diabetes after 4 months of polydipsia, polyuria and
general weakness. Symptoms disappeared after insulin
therapy was started and oral antidiabetic drugs were in-
troduced. HbA1c dropped from 15.1% to 6.1%. Several
weeks after metformin was introduced the patient began to
experience severe and disabling burning pain and cramps
in the feet. He also complained of erectile dysfunction. On
neurological examination, vibratory sense was slightly di-
minished in both feet. Patellar and Achilles reflexes were
reduced. Primary sensory modalities were preserved.
ENMG showed slowed motor conduction velocities and re-
duced amplitudes of sural nerve sensory responses, absent
peroneal sensory responses and diffuse slowing of motor
conduction velocities mostly in the lower limbs, consistent
with a predominantly axonal and sensory length-dependent
polyneuropathy. Duloxetine quickly improved the symp-
toms except for persistence of shooting pain in the legs.
Two years after diagnosis, the patient was asymptomatic
except for rare, mild foot pain. Treatment was then discon-
tinued.
Case 4
A 41-year-old woman initially sought medical advice for
weight loss of 39 kg within 12 weeks together with poly-
dipsia, polyuria and marked asthenia. Her blood glucose
level reached 25 mmol/l and HbA1c was 14.3%. Serum
anti-glutamic acid decarboxylase (GAD) antibodies were
very high (2,000 U/l, normal <10 U/l) indicating type 1 dia-
betes mellitus. With insulin therapy, her symptoms quickly
improved, with HbA1c levels returning to 5.2% within 2
weeks. After 1 month of treatment she suddenly developed
onset of burning pain associated with deep aching pain over
the four extremities and trunk with predominantly lower
limb involvement. Pain intensity was reported between 8
and 10 on a visual analogue scale and its severity caused
insomnia. There was some improvement in warm temper-
atures but worsening with contact or touch. On neurolo-
gical examination, the patient had dry skin on palms and
soles, Achilles reflexes were absent and all other tendon
reflexes were normally evoked. Blood pressures were nor-
mal without orthostatic changes. ENMG showed absent
sural nerve action potentials bilaterally, but nerve conduc-
tion parameters were otherwise normal in lower and upper
extremities. The sural nerve cutaneous silent period was
delayed and shortened, but RR interval variability and sym-
pathetic skin responses recorded from palms and soles
were normal. Intraepidermal nerve fibre density (IENFd)
values from thigh and leg skin biopsies were 11.2 IENF/
mm on the thigh (normal 20.4 ± 6.9) and 5.8 IENF/mm on
the leg (normal 11.7 ± 4.1) (fig. 1 A and B). A superficial
peroneal nerve biopsy was performed and showed loss of
large myelinated fibres as well as unmyelinated fibres, and
signs of microangiopathy (fig. 1C and D). She was given
pregabalin (150 mg/d) together with amitryptiline (75 mg/
d) and showed progressive improvement within the next 6
weeks, accompanied by an 8 kg gain in weight. One year
after onset of APDN the patient was almost asymptomatic
with normal HbA1c.
Discussion
We report four cases of APDN identified in specialised
neuromuscular units over a 5-year period. Although the
design of our study does not allow accurate epidemiologic-
al data to be calculated, because of the absence of systemat-
ic screening for APDN and possible selection biases (more
diabetic patients may be referred to our units for investig-
ation, so that their proportion in our units may be above
the prevalence of diabetes in general population), it can be
inferred from this number that the incidence of APDN is
probably below 1 in 1,000 diabetic patients, which suggests
that this condition may be very rare. However, a recent
retrospective study using a systematic approach indicates
that APDN incidence may by greatly underestimated, as it
was observed in as many as 10.9% of patients examined
for diabetic neuropathy [17]. All four patients presented
with signs associated with TIN: sudden onset of neuro-
pathic pain and rapid drop of HbA1c values from more
than 10.0% to less than 7.0% following insulin or oral an-
tidiabetic treatment, abnormal nerve conduction studies in
three patients showing features usually described for DSP
[2] and resolution of symptoms within 14 months. Severity
of TIN is associated with the magnitude of the change of
HbA1c and the estimated time to correct HbA1c. We did a
short survey of existing publications on the topic of TIN/
APDN. Overall, reports of TIN have been predominantly
small observational case studies with variable follow-up
[4–6, 8–14, 17–27]. Interestingly cases 1 and 4 developed
APDN soon after newly diagnosed and treated diabetes
type 1 as reported in few cases [7, 13]. Indeed, duration
of diabetes is not a predictive factor of developing APDN
in diabetic type 1 patients, in contrast to peripheral diabet-
ic neuropathy, screening for which is recommended only
within the first 5 years after diagnosis [28]. The neuropath-
ic pain has an acute onset, appearing within 8 weeks of
glycaemic change in contrast to the more insidious onset of
the distal sensory-motor polyneuropathy [29].
When looking more specifically at the magnitude of
change of HbA1c, all patients reported in those studies
presented with baseline HbA1c higher than 10% and a min-
imum drop of 2%. Gibbons et al. reported the largest co-
hort of patients with TIN including 16 subjects (male and
female with diabetes type 1 and 2). Mean baseline HbA1c
was 15.5% for diabetes type 1 and 13% for diabetes type
2 vs 6.4% and 7.5%, respectively, after treatment. More
recently, Gibbons et al. published a retrospective review
of 104 individuals with TIN referred to a tertiary centre
over 5 years. With a decrease in HbA1c of >4 percentage
points over 3 months the absolute risk of developing TIN
exceeded 80% [17].
Although autonomic dysfunction was not tested for in our
patients, it is classically reported in patients with APDN
and seems to be correlated with the magnitude of decrease
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in HbA1c [17]. Autonomic dysfunction is reversible in
some patients [10, 11].
At onset, TIN may present as an acute small fibre sensory
neuropathy (ASFSN), raising the problem of differential
diagnosis with the other causes of ASFSN such as Guillain-
Barré variant [30], acute steroid-responsive small fibre
sensory neuropathy [31] or non-systemic nerve vasculitis.
Several weeks after onset, the neuropathy pattern may
change, with the appearance of more classical length-de-
pendent axonal and demyelinating sensory and motor
neuropathies. Interestingly, early nerve conduction studies
in two of the patients (cases 1 and 4) were normal, as
observed in five of the six patients reported by Dabby
et al. [10], suggesting predominant involvement of small
nerve fibres at the initial stages of TIN. In case 4, specific
electrophysiological tests for small nerve fibre assessment
revealed abnormalities in the cutaneous silent period but
not the autonomic nervous system tests suggesting that, in
this patient, small nerve fibre damage involved nociceptive
fibres rather than autonomic fibres. Unlike the other three
patients, patient 4 had no conspicuous symptoms of dys-
autonomia. To explore this observation, quantification of
intraepidermal nerve fibres (IENF) was performed on skin
biopsies and showed a significant decrease in IENF dens-
ity. The role of IENF in sensory neuropathy is not well un-
derstood, but some studies found a relationship between
pain intensity and the amount of small fibre loss [32, 33].
Nerve biopsy showed not only that small fibre involvement
was not exclusive, but also signs of nerve vasculopathy, in-
dicating that axonal lesions and wallerian degeneration of
small nerve fibres may actually take place, also observed
by Gibbons et al. in 8 of their 16 patients [11].
Normal nerve conduction, despite severe clinical symp-
toms followed by resolution, has been attributed to haemo-
dynamic factors rather than changes in nerve fibre struc-
ture. Tesfaye et al. described epineural arteriovenous shunt-
ing, which results in a “steal effect”, which causes in-
creased epineural blood flow and, consequently, endoneur-
al hypoxia of small fibres [34]. Insulin therapy itself has
been reported to be the cause of arteriovenous shunting and
nerve ischaemia [35]. However, the same clinical picture
may occur without insulin treatment, and endoneural hyp-
oxia is not specific to acute painful diabetic neuropathy,
but also demonstrated in painful DSP [36]. Indeed, rapid
glycaemic control with consecutive haemodynamic com-
ponents is likely to be the cause of the hypoxia rather than
insulin itself.
Similar to TIN, it is known that intensive treatment of dia-
betes can transiently worsen pre-existing diabetic neuro-
pathy [24, 37], as observed in case 2. Many clinical studies
provide evidence for an imbalance between pro- and anti-
inflammatory cytokines in neuropathic pain [38]. Based on
these findings, it is hypothesised that hypoxia, which up-
regulates proinflammatory cytokines, associated with in-
tensive glycaemic control contributes to the pathogenesis
of TIN, in a process similar to that responsible for the early
worsening of diabetic retinopathy [11, 34].
DNC shares similarities with TIN: a sensorimotor painful
polyneuropathy following recent diabetes onset associated
with autonomic dysfunction and a history of eating dis-
order. In contrast to APDN, changes in glycaemic control
are not necessarily associated with DNC. Profound weight
loss (>10% of the body weight) is present in all patients.
Cases have been reported in patients with type 2 diabetes,
predominantly male patients in their sixth decade, and in
younger male and female type 1 diabetes patients. Weight
loss usually resolves within 1–2 years in parallel with resol-
ution of the painful neuropathic symptoms [12, 14, 19, 22,
26]. The aetiology of weight loss is unclear and has been
attributed to exaggerated protein catabolism due to poor
diabetes control, pronounced dysautonomia (gastroparesis)
and/or malabsorption as a result of exocrine pancreas insuf-
ficiency [23].
Neural and muscle biopsies in patients with DNC have
shown neurogenic atrophy in muscle involving both small
and large fibres and axonal degeneration, but no inflam-
matory and normal vasa nervosum [25]. Cases 1 and 4
showed features of DNC including severe weight loss
(cases 1 and 4), depression [12, 19, 27] and autonomic
impairment (case 1).
Hints for diagnosis and care
management of APDN
Based on previous literature, we propose diagnostic criteria
(table 2) and an algorithmic approach to the evaluation and
differential diagnosis of APDN (fig. 2). Careful history-
taking and clinical examination are essential to exclude
other potentially treatable causes of leg pain, such as peri-
pheral vascular diseases or other neurological disorders,
like lumbar stenosis, or generalised neuropathies. The
European Federation of Neurological Societies guidelines
on neuropathic pain assessment should orientate the initial
evaluation [39]. Severe pain combined with symptoms of
polyneuropathy accompanying rapid control of hyper-
glycaemia or a drop in HbA1c and/or glycaemia levels sup-
port TIN diagnosis (table 2). In addition to HbA1c and
Figure 2
Alogarithm of the approach to acute painful diabetic neuropathy
(APDN).
ANA = antinuclear antibody; B1 = vitamin B1; B12 = vitamin B12;
ENMG = electroneuromyography; N = normal; TSH = thyroid
stimulating hormone
1 Reference: Table 2
2 ADA = American diabetes association
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plasma glucose, initial laboratory tests should include vit-
amin B12 and B1 levels, thyroid stimulating hormone, ser-
um protein electrophoresis and light chain serum levels, an-
tinuclear antibody and erythrocyte sedimentation rate [40].
ENMG should be performed in all patients with symptoms
and signs of polyneuropathy, but normal results do not
rule out the diagnosis. If standard nerve conduction studies
are negative, additional, more specific functional or elec-
trophysiological investigations may be of interest in dis-
closing small nerve fibre dysfunction, such as quantitative
sensory tests [41], cutaneous silent period studies [42],
laser evoked potentials or autonomic tests [43]. Currently,
the gold standard for positive small nerve fibre neuropathy
diagnosis is a skin biopsy with IENFd determination [44].
Table 1: Patient characteristics.
Patient
ID
Age at
onset (y)/
sex
Type of
diabetes
Diabetes
duration
(y)
Initial
HbA1c
(%)
Treatment HbA1c
following
treatment
initiation
(%)
Estimated
time to
correct
HbA1c
(months)
Onset of
neuropathic
pain (weeks
from
treatment)
Time to
symptoms
resolution
(months)
Other
symptoms
ENMG/
peroneal
nerve
biopsy
Pain
medications
1 44/M Type 1 0 15.1 Insulin 7.2 5 4–6 Persistent Cachexia
(weight loss
of 11 kg)
First ENMG
normal
Second
ENMG:
axonal and
myelinic
sensory
neuropathy
Pregabalin
Gabapentin
Replaced
with
duloxetine
and opioids
2 57/M Type 2 5 12.0 Sulfonylurea
Metformin
Insulin
Lifestyle
8 8 4–6 14 Autonomic
dysfunction
– No
medication
3 49/M Type 2 0 15.1 Insulin
Metformin
6.1 3 4–6 12 Erectile
dysfuntion
ENMG:
axonal and
myelinic
neuropathy
Duloxetine
4 41/F Type 1 0 14.3 Insulin 5.2 0.5 4 12 Cachexia
(weight loss
of 39 kg)
ENMG:
Normal
IENFd:
decreased
on the thigh
and the leg
Peroneal
nerve biopsy:
loss of
myelinated
fibres
Pregabalin
Amitryptiline
ENMG = electroneuromyography; F = female; HbA1c = glycated haemoglobin; ID = identity; IENFd = intraepidermal nerve fibre density; M = male
Table 2: Proposed diagnostic criteria for acute painful diabetic neuropathy (APDN): treatment induced neuropathy and diabetic neuropathy cachexia.
Treatment induced neuropathy Diabetic neuropathy cachexia
History 1. Improved control of diabetes (type 1 or 2) following insulin or oral
antidiabetic treatment
And:
2. Onset of neuropathic pain (weeks from treatment): <6 months
3. Autonomic symptoms
4. History of eating disorder in diabetes type 1
1. Recent diabetes onset (type 1 or 2)
And:
2. Severe unintentional weight loss
3. Autonomic symptoms
4. History of eating disorder in diabetes type 1
Clinical criteria 1. Painful paraesthesia
And:
2. Symptoms suggestive of autonomic polyneuropathy
1. Painful paraesthesia
And:
2. Symptoms suggestive of autonomic polyneuropathy
And:
3. Weight loss >10% of baseline body weight
Electrodiagnostic criteria 1. Consistent with sensorimotor polyneuropathy* 1. Consistent with sensorimotor polyneuropathy*
Autonomic testing 1. Parasympathetic and sympathetic dysfunction 1. Parasympathetic and sympathetic dysfunction
Laboratory 1. Baseline HbA1c >10%
And:
2. HbA1c after treatment <9%
Or:
3. Drop of HbA1c >2% within 3 months
And:
4. Normal values of TSH, ANA, vitamin B12, vitamin B1, protein
electrophoresis
1. Baseline HbA1c ≥6.5%
And:
2. Normal values of TSH, ANA, vitamin B12, vitamin B1,
protein electrophoresis
Alternative diagnosis
excluded
Other polyneuropathies Pancreatic carcinoma, coeliac disease, other causes of
severe weight loss
* Electroneuromyography (ENMG) can be normal at the initial stage of the disease
ANA = antinuclear antibodies; HbA1c = glycated haemoglobin; TSH = thyroid stimulating hormone
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However, in-vivo confocal microscopy of the cornea might
be a valuable alternative as it gives the same information
and is noninvasive [45–47]. Moreover, as the pathogenesis
of APDN may be similar to that of diabetic retinopathy, it
is of great interest that microvascular abnormalities of the
diabetic retina were recently described to be strongly cor-
related with the corneal neuropathy observed in diabetic
neuropathies [48]. Therefore, ophthalmological assess-
ment, with classical fundoscopy and videofluoroscopy
might provide interesting pathology.
Patients with suspected DNC should have an extensive
work-up to exclude alternative diagnoses of weight loss
such as cancer or celiac disease (table 2). Autonomic test-
ing should be considered in patients with symptoms such
as orthostatic hypotension or gastrointestinal tract paresis
[15].
Treatment options for APDN are similar to those used
for chronic painful diabetic neuropathy [49, 50] (fig. 2).
They combine good glycaemic control, foot care and phar-
macological treatment. Good glycaemic control, in addi-
tion to its proven benefit in diabetic polyneuropathy, also
helps to relieve pain [51]. A previous study has highlighted
the importance of fluctuations in glucose concentrations,
which may affect neuropathic pain [52]. However, the be-
nefit of improved glycaemic control on neuropathic pain
has been investigated only in small studies. With the ex-
ceptions of hyperglycaemic emergencies, such as diabetic
ketoacidosis, it is safe to decrease glycaemic control slowly
and gradually towards the normal range.
Regular foot examination should be done by physicians
and patients should learn to inspect their feet for signs of
early infection or ulceration.
Specific pharmacological treatment of neuropathic pain in-
cludes anticonvulsants, antidepressants and opioids. The
anticonvulsant pregabalin and the antidepressant serotonin-
norepinephrine reuptake inhibitor (SNRI) duloxetine have
been approved by the American Food and Drug Adminis-
tration (FDA) for treatment of diabetic peripheral neuro-
pathic pain [53]. Antidepressants are of great help in the
management of depression in DNC and, equally, the patient
should be referred to a dietician to increase caloric intake
without worsening glycaemic control [21].
ASFSN can improve dramatically with steroid therapy,
which underscores the possible role of small nerve vessel
inflammation in the pathophysiology of APDN [31], as ob-
served in diabetic lumbosacral radiculoplexus neuropathy
[3]. On the other hand, the use of steroids in APDN is
questionable because glucose control, which is an import-
ant therapeutic target in diabetic polyneuropathy [2], may
be compromised by this treatment.
Conclusion
The major precipitating factor for TIN is a rapid drop in
glycaemia from a previously unusually high level. Previ-
ous studies such as The Diabetes Control and Complica-
tions Trial (DCTT) [54] have emphasised the benefits of
rapidly achieving glycaemic control in reducing microvas-
cular complications of diabetes type 1. However, mortality
findings in Action to Control Cardiovascular Risk in Dia-
betes (ACCORD) Trial [55] and subgroup analyses of the
Veterans Affairs Diabetes Trial (VADT) [56] suggested that
the potential risks of intensive glycaemic control may out-
weigh the benefits in some patients. Therefore the Amer-
ican Diabetes Association recommended in 2015 more or
less stringent glycaemic goals for individual patients [28].
This approach might be beneficial in reducing the risk
of TIN. Nevertheless, the recommended 3-month period
to correct HbA1c without considering the magnitude of
change of HbA1c might increase the risk of TIN in some
individuals. Awareness of this risk might in turn lead to
future adjustment of guidelines for an optimal rate of
glycaemic control that would minimise the risk of trigger-
ing TIN.
In order to better understand the underlying patho-
physiology of TIN further research should (1.) assess peri-
pheral nerve damage, not only in the course of painful
neuropathy but also prior to the symptomatic phase by use
of IENF quantification and nerve biopsy and (2.) compare
these findings with chronic painful DSP and asymptomatic
diabetic neuropathy. A better understanding of the underly-
ing pathophysiology of nerve damage and pain will help to
develop more effective treatments.
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Figures (large format)
Figure 1
Distal lower limb skin and sural nerve biopsy in normal subject compared with patient 4.
A: Distal lower limb biopsy of a normal subject (FO). Magnification 40x. Average intraepidermal nerve fibre density (IENFDd) = 12.7 s/mm.
B: Distal lower limb skin biopsy of patient 4. Note rarefaction of intraepidernal nerve fibres. Magnification 40x. Average IENFd = 2.8 s/mm.
C: Sural nerve biopsy of patient 4. Optical microspcopy (haematoxylin and eosin staining, orginal magnification 40x). Note microthrombosis of
vasa vasorum (white arrow).
D: Sural nerve biopsy of patient 4, electron microscopy. Severe loss of myelinated and unmyelinated axons.
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Figure 2
Alogarithm of the approach to acute painful diabetic neuropathy (APDN).
ANA = antinuclear antibody; B1 = vitamin B1; B12 = vitamin B12; ENMG = electroneuromyography; N = normal; TSH = thyroid stimulating
hormone
1 Reference: Table 2
2 ADA = American diabetes association
Review article Swiss Med Wkly. 2015;145:w14131
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 10 of 10
